Reach Us +44-1235425476
Imaging Tumor Response to Radiation Therapy in Liver | OMICS International | Abstract
ISSN: 2155-9619

Journal of Nuclear Medicine & Radiation Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)


Imaging Tumor Response to Radiation Therapy in Liver

Hesheng Wang*

Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, 48109, USA

*Corresponding Author:
Hesheng Wang
Department of Radiation Oncology
University of Michigan, Ann Arbor
MI, 48109, USA
E-mail: [email protected]

Received date: June 28, 2012; Accepted date: June 29, 2012; Published date: June 30, 2012

Citation: Wang H (2012) Imaging Tumor Response to Radiation Therapy in Liver. J Nucl Med Radiat Ther S6:e002.doi:0.4172/2155-9619.S6-e002

Copyright: © 2012 Wang H. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Currently, there are increasing interests in imaging tumor response to radiation therapy (RT) of hepatic cancer. Early detection of tumor response may allow a change in the treatment before completion of the prescribed therapy and maximize therapeutic efficacy of the treatment. Most importantly, once early tumor response indicates achievement of final tumor control, withholding treatment will prevent radiationinduced diseases. Response Evaluation Criteria in Solid Tumors (RECIST) which evaluates tumor response based on change in tumor size is a clinically adopted approach to determine solid tumor responses. But it may take several weeks for RECIST criteria to suggest success or failure of a treatment, which may lead to severe radiation toxicity or tumor progression due to inadequate radiation delivery. Advances of medical imaging allow high-sensitivity and high-specificity assessment of tumor biological process and, therefore, may provide surrogates of tumor response before morphological change occurs.

Recommended Conferences

Clinical Oncology & Radiation Therapy

Singapore, Singapore
Share This Page